TCM
ACHN

Teza Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Teza Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-31,038
Closed -$131K – 448
2017
Q1 		$131K Buy
+31,038
New +$129K 0.04% 462

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Teza Capital Management's ACHN Position: Q2 2017 in Review

Teza Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 31,038 shares — an estimated $131K sold.

Teza Capital Management first reported a position in ACHN in Q1 2017 and held it in 1 quarter. The position peaked at $131K in Q1 2017. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

  • Teza Capital Management reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Teza Capital Management sold 31,038 Achillion Pharmaceuticals shares in Q2 2017, an estimated $131K.
  • Teza Capital Management first reported a position in Achillion Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Teza Capital Management's Achillion Pharmaceuticals position peaked at $131K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on Teza Capital Management's 13F filing for Q2 2017.